Disappointing Results for Investigational Alzheimer’s Drug

Crenezumab, an investigational medication designed to slow or prevent Alzheimer’s disease, provides no cognitive benefit in patients at high genetic risk, new research suggests.
Medscape Medical News

Leave a Reply

Your email address will not be published.